Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Feb 16 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Isosorbide Mononitrate Extended-Release Tablets in various dosages. This medication is intended to prevent chest pain in patients with coronary artery disease and will be manufactured at their facility in Ahmedabad.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 16, 2024, titled "Zydus receives Final Approval from the USFDA for Isosorbide Mononitrate Extended-Release, Tablets USP, 30 mg, 60 mg, and 120 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases